

Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy

Submission date 05/03/2014	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 05/03/2014	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 16/12/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-intensive-treatment-and-ponatinib-for-chronic-myeloid-leukaemia-matchpoint>

Contact information

Type(s)

Scientific

Contact name

Prof Mhairi Copland

Contact details

MATCHPOINT Trial Office
Cancer Research UK Clinical Trials Unit
Centre for Clinical Haematology
Queen Elizabeth Hospital
Edgbaston
Birmingham
United Kingdom
B154 2TH

-

Matchpoint@trials.bham.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2012-005629-65

Protocol serial number

Study information

Scientific Title

Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial

Acronym

MATCHPOINT

Study objectives

The aim of this trial is to find a safe and effective dose of a drug called Ponatinib when used in combination with chemotherapy in patients with Chronic Myeloid Leukaemia (CML) whose disease has moved in to blast phase. Ponatinib is a Tyrosine Kinase Inhibitor (TKI). TKIs stop enzymes called Tyrosine Kinases from working. By stopping these enzymes from working the normal signals within the cells are disrupted. TKIs are often used in the treatment of cancers including leukaemias such as CML. 30 patients from the United Kingdom will be invited to take part in this trial.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee South Central - Berkshire B, 11/12/2013, ref.13/SC/0583

Primary study design

Interventional

Study design

Non-randomised; Interventional; Design type: Treatment

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Haematological Oncology; Disease: Leukaemia (chronic)

Interventions

12 lead ECG, 60 minutes, performed by Investigator or delegated qualified person at hospital /clinic; Additional sub-study bloods, Additional OPTIONAL blood samples for sub study - 20 minutes, performed by Investigator or delegated qualified person at hospital/clinic; Biochemistry, Biochemistry including renal and liver profile - 20 minutes, performed by Investigator or delegated qualified person at hospital/clinic; Blood samples, Full blood count with differentials - 20 minutes, performed by Investigator or delegated qualified person at hospital/clinic; Bone marrow evaluation, 60 minutes, performed by Investigator or delegated qualified person at hospital/clinic; Buccal swab, And hair follicle for DNA if buccal swab insufficient to analyse (OPTIONAL); Chemotherapy (FLAGIDA), Chemotherapy (FLAGIDA) cycle administration as per local practice; Physical examination, 30 minutes, performed by Investigator

or delegated qualified person at hospital/clinic; Ponatinib administration, Patient prescribed a bottle of tablets to last for each of the 48week cycles of trial treatment, followed by 3 monthly supplies of ponatinib on maintenance as long as the patient requires it.; Pregnancy test, 5 minutes, performed by Investigator or delegated qualified person at hospital/clinic

Follow Up Length: 36 month(s)

Study Entry: Registration only

Intervention Type

Drug

Phase

Phase I/II

Drug/device/biological/vaccine name(s)

Ponatinib

Primary outcome(s)

Efficacy; Timepoint(s): Efficacy: Complete cytogenetic response (CCyR)

Key secondary outcome(s)

1. Incidence of Cytomegalovirus (CMV) reactivation rate and Graft Versus Host Disease (GVHD); Timepoint(s): post-transplant
2. Complete Cytogenetic Response (CCyR); Timepoint(s): within 2 cycles of treatment
3. Disease free survival (DFS); Timepoint(s): 3 year
4. Haematological response; Timepoint(s): within 2 cycles of treatment
5. Major Molecular Response (MMR); Timepoint(s): within 2 cycles of treatment
6. Overall survival (OS); Timepoint(s): 3 years
7. Relapse rate post allogeneic transplant or maintenance therapy; Timepoint(s): 1 and 3 year
8. Tolerability
9. Identification of the dose of ponatinib that can be safely delivered in combination
10. Toxicity profile of ponatinib + chemotherapy (FLAG-IDA); Timepoint(s): within 6 months or up to transplant (whichever time point arrives first). Toxicities will be measure; treatment related mortality; Timepoint(s): 1 and 3 year

Completion date

26/04/2021

Eligibility

Key inclusion criteria

All of the following:

1. Ph positive or BCRABL positive CML in blastic transformation. Defined as one or more of the following being present: Blasts $\geq 30\%$ in peripheral blood or bone marrow Extramedullary blast proliferation or large foci or clusters of blasts in the bone marrow biopsy
2. Age: ≥ 18
3. Suitable for intensive chemotherapy (FLAGIDA)
4. Adequate renal function defined as serum creatinine ≤ 1.5 X upper limit of normal (ULN)
5. Adequate liver function defined as: Total bilirubin < 1.5 X ULN Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN (< 5 X ULN if liver involvement with leukaemia)
6. Normal pancreatic status Lipase ≤ 1.5 X ULN and Amylase ≤ 1.5 X ULN

7. Normal QTcF interval on screening ECG evaluation, defined as QTcF of ≤ 450 ms in males or ≤ 470 ms in females.
8. Female and male patients who are of childbearing potential must agree to use an effective form of contraception with their sexual partners throughout participation in this study until 30 days after the last dose of ponatinib.
9. Ability to comply with study procedures, in the Investigator's opinion.
10. Valid Informed Consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

17

Key exclusion criteria

1. Received chemotherapy other than hydroxycarbamide or anagrelide within 4 weeks of registration
2. Received therapy with a new TKI (i.e. changed TKI) following confirmation of blastic transformation up to two weeks of TKI therapy is allowed for those patients whose CML is in blastic phase at original diagnosis.
3. Previous treatment with intensive acute leukaemiastyle chemotherapy (FLAGIDA)
4. Prior allogeneic or autologous Stem Cell Transplant
5. Significant or active cardiovascular disease, specifically including but not restricted to:
Myocardial infarction within 6 months prior to registration
History of clinically significant atrial or ventricular arrhythmia
Unstable angina within 6 months prior to registration
Congestive heart failure within 6 months prior to registration
History of pancreatitis
6. Uncontrolled hypertriglyceridaemia (>450 mg/dL)
7. Are pregnant or lactating
8. Underwent major surgery (with the exception of minor surgical procedures, such as catheter placement or Bone Marrow biopsy) within 14 days prior to registration
9. Suffer from any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the study treatment

Date of first enrolment

02/12/2014

Date of final enrolment

26/04/2018

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Cancer Research UK Clinical Trials Unit

Birmingham

United Kingdom

B15 2TT

Sponsor information

Organisation

University of Birmingham (UK)

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Industry

Funder Name

Incyte Corporation

Funder Name

Bloodwise

Alternative Name(s)**Funding Body Type**

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		10/12/2021	16/12/2021	Yes	No
HRA research summary			28/06/2023	No	No